Hemophilia is an autosomal recessive disease linked to the X chromosome caused by the mutation in the gene F8 or F9. It is a chronic, progressive and high-cost disease. The annual incidence is 1 in 5,000 births and the prevalence is estimated at 1 in 12,000 worldwide.

OBJECTIVES

: To estimate the direct costs of a cohort of patients with Hemophilia affiliated with a health insurer in Colombia during the years 2010-2017.

METHODS

A retrospective study of a dynamic cohort of 176 patients distributed in 15 cities of the country, affiliated with a health insurer in Colombia, was carried out during 6 years. Demographic characteristics, average annual costs per health service and per patient were estimated. Costs were adjusted for inflation and expressed in US dollars for the year 2017

RESULTS

: Prevalence of Hemophilia type A and B for men was (4.5 and 1.1) and for women (1.2 and 0.04) per 100,000 members respectively. Average age was 23.1 years (SD 18.2) for Hemophilia A and 17.3 years (SD 13.8) for Hemophilia B. The cities with the highest concentration of patients were Bogotá (38.6%), Barranquilla (17.0%) and Bucaramanga (11.3%). Average cost of annual care for patients in the cohort was USD 4,191,993 (SD 1,164,282) for Hemophilia A USD 886,214 (SD 194,882) for Hemophilia B, distributed mainly in: Clotting Factors (93.8%), package of clinical services (including laboratories, diagnostic imaging, hematology, home care etc.) (5.1%), hospitalization (0.4%), surgery (0.1%), dentistry (0.1%) and others (0.5%). The average cost per patient annual was $ 42,226 (SD 8,663) for Hemophilia A and $ US 38,594 (SD 16,889) for Hemophilia B.

CONCLUSIONS

: The annual average cost per patient of Hemophilia A and B in the evaluated cohort corresponds to the annual per capita premium of 167 and 153 patients respectively, for the year 2017.